A COVID-19 vaccine may be available to some people before Christmas, said Kate Bingham, chair of the UK government’s vaccine task force in an interview. However, a launch in early 2021 is more likely, he added.
“The first phase III efficacy data for the main vaccine candidates should be available by the end of 2020, subject to accumulating sufficient infection rates within clinical trial cohorts to demonstrate the efficacy of the vaccines. The endpoint The main thing is to show that the vaccine can protect against SARS-CoV-2 infection and reduce the burden of symptoms, “wrote Bingham in the medical journal. The lancet on Tuesday.
Two phase III efficacy clinical trials are currently underway in the UK: the AstraZeneca Oxford adenovirus vector vaccine and the Novavax protein adjuvant vaccine.
“If the first two vaccines, or any of them, show that they are safe and effective, I think there is a chance that the vaccine launch will start on this side of Christmas, but otherwise I think it is more realistic to expect that let it be so early next year, “Kate Bingham said on BBC television.
The first generation of vaccines to fight COVID-19 infection may not be perfect and may not work for everyone, you mentioned earlier. “The first generation of vaccines are likely to be imperfect, and we must be prepared that they do not prevent infection but reduce symptoms, and even then they may not work for everyone or for a long time.”
British pharmaceutical giant AstraZeneca previously said that trials of its coronavirus vaccine, started by the University of Oxford, had shown “encouraging” responses among the elderly and younger participants.
The UK Vaccine Task Force ensured access to six vaccines (out of more than 240 vaccines in development) in four different formats – adenoviral vectors, mRNAs, adjuvanted proteins, and whole inactivated viral vaccines, which show promise in different ways.
The United Kingdom is committed to ensuring that all people at risk of SARS-CoV-2 infection, anywhere in the world, have access to a safe and effective vaccine, he mentioned in the journal.
Pfizer Says COVID-19 Vaccine Still Possible in 2020
Pfizer CEO Albert Bourla expressed optimism about the possibility of providing a coronavirus vaccine in 2020. “We have reached the last mile here,” Bourla said.
The pharmaceutical giant could supply about 40 million doses in the United States in 2020 if clinical trials progress as expected and regulators approve a vaccine, he added. But Bourla said the company had not yet reached key benchmarks for evaluating the vaccine’s efficacy. He said the company expects to apply for an emergency use authorization for its COVID-19 vaccine in the third week of November, roughly in line with previous schedules.
.
